NASDAQ
117.17USD
-1.91 (-1.60%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
3.9B
P/E
—
EPS
—
Beta
1.27
52W range
100.846-212
Day range
116.50–120.11
Open
118.14
Prev close
119.08
Volume
464K
Avg volume
574.3K
Dividend
0.00
IPO
2016-10-20
https://www.globenewswire.com/news-release/2026/07/29/3335691/0/en/Kuehn-Law-Encourages-Investors-of-CG-Oncology-Inc-to-Contact-Law-Firm.html · 7/29/2026-0.80
https://www.globenewswire.com/news-release/2026/07/02/3321521/0/en/Kuehn-Law-Encourages-Investors-of-NuScale-Power-Corporation-to-Contact-Law-Firm.html · 7/2/2026-0.80
https://www.globenewswire.com/news-release/2026/06/30/3320169/0/en/Kuehn-Law-Encourages-Investors-of-Dick-s-Sporting-Goods-Inc-to-Contact-Law-Firm.html · 6/30/2026-0.50
https://www.zacks.com/stock/news/2914838/wall-street-analysts-predict-a-57-21-upside-in-irhythm-hldgs-irtc-here-s-what-you-should-know?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|consensus_price_target-2914838 · 5/5/2026+0.80
https://www.zacks.com/stock/news/2914128/irtc-stock-up-on-q1-earnings-revenue-beat-fy26-outlook-raised?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_article-2914128 · 5/4/2026+0.80
https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-irhythm-technologies-inc-to-contact-law-firm-302738366.html · 4/9/2026-0.80
https://www.zacks.com/stock/news/2893267/here-s-why-you-should-retain-irtc-stock-in-your-portfolio-for-now?cid=CS-STOCKNEWSAPI-FT-analyst_blog|rank_focused-2893267 · 4/1/2026+0.60
https://www.globenewswire.com/news-release/2026/01/28/3227947/0/en/Kuehn-Law-Encourages-Investors-of-iRhythm-Technologies-Inc-to-Contact-Law-Firm.html · 1/28/2026-1.00
https://www.defenseworld.net/2026/01/24/irhythm-technologies-nasdaqirtc-given-average-recommendation-of-moderate-buy-by-analysts.html · 1/24/2026+0.60
https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-irhythm-technologies-inc-to-contact-law-firm-302655568.html · 1/7/2026-0.80
https://www.defenseworld.net/2025/12/20/assenagon-asset-management-s-a-invests-13-39-million-in-irhythm-technologies-irtc.html · 12/20/2025+0.30
https://www.defenseworld.net/2025/12/07/head-to-head-survey-inspire-medical-systems-nyseinsp-versus-irhythm-technologies-nasdaqirtc.html · 12/7/2025+0.00
iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
